Darryl Vleeming - Aurora Cannabis Chief Information Officer
| ACB Stock | USD 6.97 0.39 5.30% |
Executive
Darryl Vleeming is Chief Information Officer of Aurora Cannabis since 2017.
| Tenure | 7 years |
| Address | 2207 90B Street SW, Edmonton, AB, Canada, T6X 1V8 |
| Phone | 855 279 4652 |
| Web | https://www.auroramj.com |
Aurora Cannabis Management Efficiency
The company has Return on Asset of (0.0826) % which means that on every $100 spent on assets, it lost $0.0826. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.3728) %, meaning that it generated no profit with money invested by stockholders. Aurora Cannabis' management efficiency ratios could be used to measure how well Aurora Cannabis manages its routine affairs as well as how well it operates its assets and liabilities. As of May 3, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Aurora Cannabis' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 13.3 M, whereas Total Assets are forecasted to decline to about 982.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lisa Wilson | Eagle Pharmaceuticals | N/A | |
| Daniel Martin | Deciphera Pharmaceuticals LLC | 49 | |
| Paul Bruinenberg | Eagle Pharmaceuticals | 53 | |
| Melissa Forst | Deciphera Pharmaceuticals LLC | N/A | |
| Carlos Russo | Procaps Group SA | 39 | |
| Jeffrey JD | Deciphera Pharmaceuticals LLC | N/A | |
| Kevin Brodbeck | Deciphera Pharmaceuticals LLC | N/A | |
| Matthew MD | Deciphera Pharmaceuticals LLC | 68 | |
| Roxanne Jenkins | Silver Spike Investment | 38 | |
| Oliver Rosen | Deciphera Pharmaceuticals LLC | 52 | |
| Christopher Morl | Deciphera Pharmaceuticals LLC | 59 | |
| Umesh Mahajan | Silver Spike Investment | 53 | |
| Margarida Duarte | Deciphera Pharmaceuticals LLC | N/A | |
| Jose Vieira | Procaps Group SA | 58 | |
| Camilo Camacho | Procaps Group SA | 50 | |
| Dashyant Dhanak | Deciphera Pharmaceuticals LLC | 63 | |
| Reed McClung | Eagle Pharmaceuticals | N/A | |
| Steven Krill | Eagle Pharmaceuticals | 56 | |
| Valentin MD | Eagle Pharmaceuticals | N/A | |
| Debra Hussain | Eagle Pharmaceuticals | N/A | |
| Gaozhong Zhu | Eagle Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.0826 |
Aurora Cannabis Leadership Team
Elected by the shareholders, the Aurora Cannabis' board of directors comprises two types of representatives: Aurora Cannabis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aurora. The board's role is to monitor Aurora Cannabis' management team and ensure that shareholders' interests are well served. Aurora Cannabis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aurora Cannabis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Victoria Thomas, Six Degrees Investor Relations | ||
| Hoa Nguyen, Chief Accounting Officer | ||
| Andrew Vallis, Member of the Board of Management | ||
| Simona King, Chief Officer | ||
| Angang Shen, Director | ||
| Darren Karasiuk, Executive Vice President - Adult Usage | ||
| Huy Tran, Chairman of the Board of Management | ||
| Nilda Rivera, Vice President - Finance, Corporate Secretary | ||
| Muhan Liu, Director | ||
| Carey Squires, Executive Vice President of Corporate Development and Strategy | ||
| Toai Nguyen, Deputy General Director, Information Disclosure Officer | ||
| Michael Singer, Executive Chairman of the Board, Interim Chief Executive Officer | ||
| Jillian Swainson, Chief Legal Officer, Corporate Secretary | ||
| Andre Jerome, Executive Vice President - Global Business Development | ||
| Jijing Niu, Non-Executive Director | ||
| Ashley Jones, Operations Manager | ||
| Marc Lakmaaker, VP, Investor Relations | ||
| Nathalie Clark, General VP | ||
| Steve Dobler, President Director | ||
| Jonathan Page, Chief Scientific Officer | ||
| Nicholas Yeak, Company Secretary | ||
| Nick Whitehead, Vice President - Market Development | ||
| Han Nguyen, Deputy General Director | ||
| John Barnet, Chief Cultivator | ||
| Long Nguyen, Member of the Board of Management | ||
| Anthony Khama, Chairman, A-Cap Botswana Pty Ltd | ||
| Savior Joseph, Senior Vice President - Global Marketing | ||
| Glen Ibbott, Chief Financial Officer | ||
| John Bean, CFO | ||
| Diane Jang, Director | ||
| Michael Detlefsen, Independent Director | ||
| Darryl Vleeming, Chief Information Officer | ||
| Rick Savone, Senior Vice President - Global Government Relations | ||
| Norma Beauchamp, Independent Director | ||
| Henry Stacpoole, Non-Executive Independent Director | ||
| Shane Morris, Senior Vice President - Product Development and Regulatory Affairs | ||
| Ronald Funk, Independent Chairman of the Board | ||
| Paul Thomson, CEO, Director | ||
| Allan Cleiren, Chief Operational Officer | ||
| Toan Do, General Director | ||
| Jason Dyck, Independent Director | ||
| Dominic Scriven, Member of the Board of Management | ||
| Charles Rifici, Director | ||
| Lori Schick, Executive Resources | ||
| Hung Tran, Member of the Board of Management | ||
| Chenghu Zhu, Non-Executive Director | ||
| Bill Macdonald, Secretary | ||
| John FisherStamp, Director | ||
| Alex Miller, Executive Chain | ||
| Dave Aird, Executive Technology | ||
| Paul Woolrich, Executive Director | ||
| Miguel Martin, Chief Executive Officer, Director | ||
| Tai Bui, Permanent Deputy General Director, Director of Corporate Clients Division | ||
| Adam Szweras, Independent Director | ||
| Tuan Dam, Deputy General Director, Member of the Board of Management | ||
| Neil Belot, Chief Global Business Development Officer | ||
| Debra Wilson, Chief Human Resource Officer | ||
| Hai Nguyen, Deputy General Director | ||
| Ananth Krishnan, Vice Relations | ||
| Theresa Firestone, Independent Director | ||
| Lance Friedmann, Independent Director | ||
| Margaret Atkins, Independent Director | ||
| Cameron Battley, Chief Corporate Officer | ||
| Thomas Larssen, President of Aurora Larssen Projects Ltd | ||
| Alain Cany, Member of the Board of Management | ||
| Dieter MacPherson, Vice President - Production | ||
| Hoa Dinh, Member of the Board of Management | ||
| Terry Booth, Chief Executive Officer, Director | ||
| Kien Tran, Member of the Board of Management | ||
| Thuy Dang, Member of the Board of Management | ||
| Michelle Lefler, Vice Relations | ||
| Tuan Huynh, Deputy General Director, Director of Hanoi branch | ||
| Paul Ingram, Non-Executive Independent Director | ||
| Kelly Narine, Vice President - Research |
Aurora Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aurora Cannabis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.0826 | ||||
| Profit Margin | 1.52 % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 397.94 M | ||||
| Shares Outstanding | 54.54 M | ||||
| Shares Owned By Institutions | 7.06 % | ||||
| Number Of Shares Shorted | 8.14 M | ||||
| Price To Earning | 46.94 X | ||||
| Price To Book | 0.95 X |
Pair Trading with Aurora Cannabis
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aurora Cannabis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aurora Cannabis will appreciate offsetting losses from the drop in the long position's value.Moving together with Aurora Stock
| 0.87 | DXR | Daxor | PairCorr |
Moving against Aurora Stock
| 0.87 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.87 | INFU | InfuSystems Holdings Earnings Call Today | PairCorr |
| 0.76 | NIO | Nio Class A Trending | PairCorr |
| 0.71 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.7 | NYXH | Nyxoah Financial Report 21st of May 2024 | PairCorr |
The ability to find closely correlated positions to Aurora Cannabis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aurora Cannabis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aurora Cannabis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aurora Cannabis to buy it.
The correlation of Aurora Cannabis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aurora Cannabis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aurora Cannabis moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aurora Cannabis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurora Cannabis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Aurora Stock refer to our How to Trade Aurora Stock guide.Note that the Aurora Cannabis information on this page should be used as a complementary analysis to other Aurora Cannabis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Aurora Stock analysis
When running Aurora Cannabis' price analysis, check to measure Aurora Cannabis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurora Cannabis is operating at the current time. Most of Aurora Cannabis' value examination focuses on studying past and present price action to predict the probability of Aurora Cannabis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurora Cannabis' price. Additionally, you may evaluate how the addition of Aurora Cannabis to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Aurora Cannabis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurora Cannabis. If investors know Aurora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurora Cannabis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.92) | Earnings Share (57.95) | Revenue Per Share 6.784 | Quarterly Revenue Growth 0.055 | Return On Assets (0.08) |
The market value of Aurora Cannabis is measured differently than its book value, which is the value of Aurora that is recorded on the company's balance sheet. Investors also form their own opinion of Aurora Cannabis' value that differs from its market value or its book value, called intrinsic value, which is Aurora Cannabis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurora Cannabis' market value can be influenced by many factors that don't directly affect Aurora Cannabis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurora Cannabis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurora Cannabis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurora Cannabis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.